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Abstract 
 
Objectives: To investigate whether measurement of maternal serum placental growth factor 
(PLGF) at 11-13 weeks’ gestation improves the performance of screening for stillbirths that is 
achieved by a combination of maternal factors and first trimester biomarkers such as maternal 
serum pregnancy associated plasma protein-A (PAPP-A), ductus venosus pulsatility index for 
veins (DV-PIV) and uterine artery pulsatility index (UT-PI) PI and to evaluate the performance 
of screening of this model for all stillbirths and those due to impaired placentation and 
unexplained causes. 
  
Methods: This was a prospective screening study of 45,452 singleton pregnancies including  
45,225 live births and 227 (0.49%) antepartum stillbirths; 131 (58%) were secondary to 
impaired placentation and 96 (42%) were due to other or unexplained causes. Multivariate 
logistic regression analysis was used to determine whether the addition of maternal serum 
PLGF improved the performance of screening that was achieved by a combination of maternal 
factors and PAPP-A, DV-PIV and UT-PI. 
 
Results: Significant contribution to the prediction of stillbirths was provided by maternal factor 
derived a priori risk and MoM values of PLGF, DV-PIV and UT-PI but not serum PAPP-A. A 
model combining these variables predicted 42% of all stillbirths and 61% of those due to 
impaired placentation, at false positive rate of 10%; within the impaired placentation group the 
detection rate of stillbirth at <32 weeks’ gestation was higher than that of stillbirth at >37 weeks 
(71% vs 46%; p=0.031). 
 
Conclusions: The results of our study demonstrate that a high proportion of stillbirths due to 
impaired placentation can be effectively identified in the first trimester of pregnancy. The extent 
to which such stillbirths could be prevented remains to be determined.  
  
Introduction 
 
Antepartum stillbirths can be broadly classified into those thought to be the consequence of 
impaired placentation and those due to other causes or being unexplained; the rationale of 
categorizing stillbirths according to the likely underlying cause is that antenatal interventions 
and preventive strategies could potentially be undertaken more effectively.1-3 Screening for 
stillbirth in early pregnancy by a combination of maternal factors, including weight, racial origin, 
method of conception, cigarette smoking and history of diabetes mellitus, chronic 
hypertension, systemic lupus erythematosus and antiphospholipid syndrome, predicted about 
30% of stillbirths, at false positive rate (FPR) of 10%.4 A first-trimester screening study 
combining maternal factors with measurements of uterine artery pulsatility index (UT-PI), fetal 
ductus venosus pulsatility index for veins (DV-PIV) and maternal serum pregnancy associated 
plasma protein-A (PAPP-A), which provide indirect information on placentation, reported that, 
at FPR of 10%, the detection rate (DR) of stillbirth due to impaired placentation improved to 
55%, whereas the DR of stillbirths due to other cases or those that were unexplained was only 
24%.5    
 
Placental growth factor (PLGF) is an angiogenic protein produced by the placenta and is 
implicated in trophoblastic invasion of maternal spiral arteries.6-8 Maternal serum levels at 11-
13 weeks’ gestation are decreased in pregnancies with impaired placentation that develop 
preeclampsia (PE) and those that deliver small for gestational age (SGA) neonates.9-11  
 
The objective of this study was to investigate whether measurement of maternal serum PLGF 
at 11-13 weeks’ gestation improves the performance of screening for stillbirths that is achieved 
by a combination of maternal factors and PAPP-A, DV-PIV and UT-PI and evaluate the 
performance of screening of this model for all stillbirths and those due to impaired placentation 
and unexplained or other causes. 
 
 
Methods 
 
Study population 
 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for routine pregnancy care at 11+0-13+6 weeks’ gestation at 
King’s College Hospital and Medway Maritime Hospital, United Kingdom. We recorded 
maternal characteristics and medical history and performed combined screening to estimate 
risks for fetal aneuploidies based on maternal age, fetal nuchal translucency (NT) thickness 
and measurement of maternal serum pregnancy associated plasma protein-A (PAPP-A) and 
free ß-human chorionic gonadotropin (hCG).12 Transabdominal colour Doppler ultrasound was 
performed to measure ductus venosus pulsatility index for veins (DV-PIV) and uterine artery 
pulsatility index (UT-PI).13,14 Maternal serum concentration of free ß-hCG, PAPP-A and PLGF 
was measured using automated analysers which provide reproducible results within 10 
minutes of blood sampling (DELFIA Xpress system, PerkinElmer Life and Analytical Sciences, 
Waltham, MA, USA or Cobas e411 system, Roche Diagnostics, Penzberg, Germany). 
Gestational age was determined from measurement of fetal crown-rump length (CRL).15 The 
women were screened between March 2006 and October 2015 and gave written informed 
consent to participate in the study, which was approved by the Ethics Committee.  
 
The inclusion criteria for the study were singleton pregnancies that delivered a phenotypically 
normal live birth or stillbirth at >24 weeks’ gestation. We excluded pregnancies with 
aneuploidies, major fetal abnormalities, those ending in a miscarriage, termination of 
pregnancy or stillbirths due to intrapartum causes. Data on pregnancy outcome were obtained 
from the maternity hospital records or the general practitioners of women. The hospital 
maternity records of all women with antepartum stillbirths were reviewed to determine if the 
death was associated with preeclampsia, abruption or the birthweight was <10th percentile for 
gestational age 16 or it was due to other reasons or unexplained.  
 
Statistical analysis 
 
Data from continuous variables were expressed as medians and interquartile ranges and from 
categorical data as n (%). Comparison of the maternal characteristics between the outcome 
groups was by the χ2-square test or Fisher’s exact test for categorical variables and Kruskal-
Wallis or Mann-Whitney U-test for continuous variables, respectively. A p value of < 0.05 was 
considered significant. Post-hoc Bonferroni correction was used for multiple comparisons. 
 
The measured values of PAPP-A, PLGF, UT-PI and DV-PIV were log10 transformed to make 
their distributions Gaussian and each value was expressed as a multiple of the normal median 
(MoM) after adjustment for those characteristics that provide a substantial contribution to the 
log10 transformed value.13,17-19 The a priori risk for stillbirths was estimated from the algorithm 
derived from multivariate logistic regression analysis of maternal characteristics and history 
as previously described.4 Univariate and multivariate logistic regression analysis was then 
used to determine if the maternal factor-derived logit (a priori risk), log10 MoM value of each 
biochemical and biophysical marker had a significant contribution in stillbirths and whether the 
addition of serum PLGF (log10 MoM) improved the performance of screening that was achieved 
by a combination of maternal factors and PAPP-A, DV-PIV and UT- PI. The significant 
predictors in the multivariate analysis were used to determine the patient-specific risk of 
stillbirth using the equation odds/(1+odds), where odds=eY and Y was estimated from the 
coefficients of variables in the logistic regression analysis. The distribution of risks was used 
to determine the performance of screening by receiver operating characteristic (ROC) curves 
analysis and the DR and FPR were estimated. The significane of improvement in performance 
of screening by additional of maternal serum PLGF was assessed by comparison of the areas 
under the ROC curves (AUROC).20  
 
The statistical software package SPSS 22.0 (IBM SPSS Statistics for Windows, Version 22.0. 
Armonk, NY: IBM Corp, 2013) and Medcalc (Medcalc Software, Mariakerke, Belgium) were 
used for the data analyses. 
 
 
Results 
 
Study population 
 
The 45,452 singleton pregnancies fulfilling the entry criteria included 45,225 live births and 
227 (0.49%) antepartum stillbirths; 131 (58%) were secondary to impaired placentation and 
96 (42%) were due to other or unexplained causes. The maternal and pregnancy 
characteristics of the outcome groups are compared in sTable 1.  
 
Biomarkers in outcome groups 
 
In the stillbirth group, compared to live births, there was lower serum PAPP-A MoM (0.85 vs 
1.00; p<0.0001) and PLGF MoM (0.78 vs 1.00; p<0.0001) and higher UT-PI MoM (1.23 vs 
1.00, p<0.0001), but there was no significant difference in DV-PIV MoM. In the stillbirths due 
to impaired placentation, compared to live births, there was lower serum PAPP-A MoM (0.70 
vs 1.00; p<0.0001) and PLGF MoM (0.63 vs 1.00; p<0.0001) and higher DV-PIV MoM (1.05 
vs 1.00; p<0.0001) and UT-PI MoM (1.39 vs 1.00, p<0.0001); in the stillbirths due to 
unexplained causes there were no significant differences from live births in any of the 
biomarkers (sTable 2, Figure 1). 
 
Prediction of stillbirth and performance of screening 
 
The results of univariate and multivariate regression analysis are shown in sTable 3. In the 
multivariate regression analysis, there was a significant contribution to the prediction of 
stillbirth due to impaired placentation from maternal factor derived a priori risk and MoM values 
of PLGF, DV-PIV and UT-PI, but not serum PAPP-A (R2=0.193; p<0.0001). Multivariate 
regression analysis demonstrated that the odds ratio for maternal factors, DV-PIV, UT-PI and 
PLGF were 9.0 (95% CI 5.3-15.3), 2.7 (95% CI 1.8-4.0), 7.7 (95% CI 4.8-12.3) and 0.04 
(95%CI 0.02-0.08), respectively. In a model without PLGF a change of each unit of PAPP-A 
MoM was associated with an odds ratio for stillbirth of 0.46. 
 
The performance of screening for stillbirth from maternal factors and biomarkers is shown in 
Table 1. Combinated screening by maternal factors, PAPP-A, DV-PI and UT-PI detected 50% 
of all stillbirths due to impaired placentation, at a FPR of 10% (AUROC curve 0.809, 95CI% 
0.767-0.850). Addition of serum PLGF, which resulted in making the contribution of serum 
PAPP-A non-significant, improved the DR to 61% (AUROC curve 0.852, 95% CI 0.816-0.888).  
In the impaired placentation group, screening by maternal factors, PLGF, DV-PI and UT-PI, 
the DR of stillbirths at < 32 weeks’ gestation was higher than those at >37 weeks (71% vs 
46%; p=0.031). 
 
 
Discussion 
 
Main findings of the study 
 
The findings of the study demonstrate that in our large study population from hospitals in the 
UK, 58% of antepartum stillbirths are due to impaired placentation and 42% are unexplained 
or due to other causes. A model which combines maternal factors, serum PLGF, UT-PI and 
fetal DV-PIV at 11-13 weeks’ gestation can potentially predict about 60% of stillbirths due to 
impaired placentation, at 10% FPR; the performance of screening is better for stillbirths at <32 
weeks’ gestation (71%) compared to those at term (46%). Although serum PAPP-A on its own 
or in combination with UT-PI and DV-PIV is useful in the early prediction of stillbirth, its 
contribution is not significant once serum PLGF is added to the model. In the multivariate 
regression model in this study, the odds ratio for stillbirth with each unit of change in serum 
metabolite MoM was 0.46 for PAPP-A and 0.04 for PLGF, with the implication that the 
contribution of PLGF was 10-fold higher than that of PAPP-A. 
 
Strengths and limitations 
 
The strengths of this screening study are first, examination of a large population of pregnant 
women attending for routine assessment at 11-13 weeks’ gestation, second, systematic 
recording of data on maternal characteristics and medical history to identify known risk factors 
associated with stillbirth, third, use of a specific methodology and appropriately trained doctors 
to measure DV-PIV and UT-PI, fourth, use of automated machines to provide accurate 
measurement within 40 minutes of sampling of maternal serum concentration of metabolites 
that have been shown to be altered in pregnancies associated with impaired placentation, fifth, 
expression of the values of biomarkers as MoMs after adjustment for factors that affect the 
measurements, and sixth, use of multivariate regression analysis to take into account possible 
interrelations between the different variables to define the relative predictive value of each 
factor.  
 
A potential limitation of the study is that the performance of screening by a model derived and 
tested using the same dataset is overestimated; consequently, the model needs validation 
from prospective studies. 
 
Comparison with other studies 
 
Previous studies reported that at 11-13 weeks’ gestation serum PLGF is reduced in 
pregnancies with impaired placentation resulting in PE or the birth of SGA neonates.9-11,21 The 
performance of early screening for stillbirth due to impaired placentation by an algorithm 
incorporating serum PLGF is superior to that relying on maternal factors alone or a 
combination of maternal factors with UT-PI, DV-PIV and serum PAPP-A.4,5 This is not 
surprising since we have previously reported that in early screening for PE by a combination 
of maternal factors and biomarkers serum PLGF had a better performance than serum PAPP-
A.11 
 
Clinical implications of the study 
 
The results of our study demonstrate that a high proportion of stillbirths due to impaired 
placentation can be effectively identified in the first trimester of pregnancy. In the case of PE 
there is widely accepted process of screening which is based on a combination of maternal 
factors alone; we have demonstrated that the performance of screening by a combination of 
maternal factors with biomarkers including UT-PI and PLGF, is by far superior to that which 
relies on maternal factors alone.11,22 It is therefore likely that combined screening will be widely 
adopted, especially because there is evidence that pharmacological interventions in the high-
risk group, by such drugs as low-dose aspirin starting at <16 weeks’ gestation, could 
potentially improve placentation and reduce the associated risk of PE, SGA and stillbirths by 
more than 50%.23 
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Table 1. Performance of screening for stillbirths at various cut-offs of gestational age based 
on maternal factors and combination of maternal factors with biochemical and biophysical 
markers at 11-13 weeks’ gestation at fixed false positive rates (FPR). 
 
Outcome  N AUROC (95% CI) 
Detection rates (95% CI) 
5% FPR 10% FPR 
All stillbirths 227  
     Maternal factors  0.647 (0.607-0.686) 19.4 (14.3-24.5) 30.4 (24.4-36.4) 
     + UT PI + DV PIV + PlGF  0.731 (0.693-0.769) 31.7 (25.7-37.8) 41.9 (35.5-48.3)  
Unexplained    
     Maternal factors 96 0.625 (0.567-0.683) 14.6 (7.5-21.7) 26.0 (17.2-34.8) 
Abnormal placentation  
All stillbirths 131    
     Maternal factors  0.663 (0.610-0.716) 22.9 (15.7-30.1) 33.6 (25.5-41.7) 
     + PlGF  0.814 (0.777-0.852) 40.5 (32.1-48.9) 51.1 (42.5-59.7) 
     + DV-PIV  0.684 (0.631-0.737) 28.2 (20.5-35.9) 37.4 (29.1-45.7) 
     + UT-PI  0.790 (0.748-0.832) 35.1 (26.9-43.3) 45.8 (37.3-54.3) 
     + PlGF + DV-PIV  0.820 (0.782-0.858) 42.0 (33.6-50.5) 51.4 (42.8-60.0) 
     + UT-PI + DV-PIV  0.795 (0.754-0.836) 36.6 (28.1-44.5) 48.1 (39.5-56.7) 
     + PlGF + UT-PI  0.848 (0.811-0.884) 47.9 (39.4-56.5) 60.8 (52.4-69.2) 
     + UT-PI + DV-PIV + PlGF  0.852 (0.816-0.888) 48.1 (36.2-60.0) 61.1 (49.5-72.7) 
< 32 weeks 68    
     Maternal factors  0.664 (0.587-0.741) 29.4 (18.6-40.2) 36.8 (25.3-48.3) 
     + UT-PI + DV-PIV + PlGF  0.900 (0.859-0.940) 61.8 (50.3-73.4) 70.6 (59.8-81.4) 
< 37 weeks 98    
     Maternal factors  0.666 (0.604-0.727) 24.5 (16.0-33.1) 32.7 (23.4-42.0) 
     + UT-PI + DV-PIV + PlGF  0.875 (0.835-0.915) 54.1 (44.2-64.0) 66.3 (56.9-75.7) 
> 37 weeks 33    
     Maternal factors  0.655 (0.551-0.758) 18.2 (5.1-31.4) 36.4 (20.0-52.8) 
     + UT-PI + DV-PIV + PlGF  0.785 (0.710-0.860) 30.3 (14.6-45.9) 45.5 (28.5-62.5) 
 
AUROC=area under receiver operating characteristic curves; CI= confidence interval; FPR = 
False positive rate; PAPP-A= pregnancy associated plasma protein-A; UT-PI=Uterine artery 
pulsatility index; DV-PIV = Ductus venosus pulsatility index for veins 
Supplementary Table 1. Maternal and pregnancy characteristics in pregnancies that had a stillbirth, stratified according to sub-groups, compared 
with pregnancies that had a live births 
 
Maternal characteristics 
Live births 
(n=45,225) 
All stillbirths 
(n=227) 
Unexplained 
(n=96) 
Impaired placentation 
(n=131) 
Age, median (IQR) 31.1 (26.5-34.8) 32.6 (26.7-36.1) 32.5 (25.9-36.2) 32.7 (27.0-36.0) 
Weight, median (IQR) 67.0 (59.3-78.0) 73.6 (63.6-83.4)** 71.3 (62.9-82.8)† 74.0 (63.6-85.0)* 
Height, median (IQR) 1.65 (1.60-1.69) 1.65 (1.60-1.68) 1.66 (1.60-1.68) 1.65 (1.60-1.68) 
Racial origin     
     Caucasian, n (%) 32,834 (72.6) 122 (53.7) 55 (57.3) 67 (51.1) 
     Afro-Caribbean, n (%) 8,359 (18.5) 86 (37.9)** 34 (35.4)* 52 (39.7)* 
     South Asian, n (%) 1,927 (4.3) 8 (3.5) 3 (3.1) 5 (3.8) 
     East Asian, n (%) 929 (2.1) 4 (1.8) 1 (1.0) 3 (2.3) 
     Mixed, n (%) 1,176 (2.6) 7 (3.1) 3 (3.1) 4 (3.1) 
Method of conception     
     Spontaneous, n (%) 43,877 (97.0) 214 (94.3) 91 (94.8) 123 (93.9) 
     Assisted conception, n (%) 1,348 (3.0) 13 (5.7) 5 (5.2) 8 (6.1) 
Cigarette smoking, n (%) 4,335 (9.6) 25 (11.0) 9 (9.4) 16 (12.2) 
Chronic hypertension, n (%) 699 (1.5) 15 (6.6)** 1 (1.0) 14 (10.7)* 
SLE / APS, n (%) 97 (0.2) 2 (0.9) 0 2 (1.5) † 
Diabetes mellitus, n (%) 435 (1.0) 9 (4.0)* 5 (5.2)* 4 (3.1)† 
Parity     
     Nulliparous, n (%) 21,266 (47.0) 109 (48.0) 46 (47.9) 63 (48.1) 
     Previous miscarriage, n (%) 574 (1.3) 2 (0.9) 1 (1.0) 1 (0.8) 
     Previous stillbirth, n (%) 360 (0.8) 10 (4.4)** 3 (3.1)† 7 (5.3)* 
     Previous SGA, n (%) 1,494 (3.3) 9 (4.0) 2 (2.1) 7 (5.3) 
Inter-pregnancy interval, median (IQR)a 1.1 (0.0-3.1) 1.0 (0.0-4.4) 1.2 (0.0-4.0) 0.8 (0.0-4.5) 
 
Post hoc Bonferroni correction for multiple comparisons; † = p<0.025; * = p< 0.01; ** = p< 0.001 
 
IQR=interquartile range; SLE=systemic lupus erythematosus; APS=anti-phospholipid syndrome; SGA= small for gestational age 
a Inter-pregnancy interval median (IQR) reported for parous women 
Supplementary Table 2. Median and interquartile range of biochemical and biophysical markers in pregnancies with livebirths compared to 
those that had a stillbirth 
Biomarker 
Livebirths 
(n=45,225) 
All stillbirths 
(n=227) 
Unexplained 
(n=96) 
Abnormal placentation 
(n=131) 
Pregnancy associated plasma protein-A (MoM) 1.00 (0.69-1.43) 0.85 (0.53-1.23)*** 1.04 (0.70-1.44) 0.69 (0.46-1.10)*** 
Placental growth factor (MoM) 1.00 (0.78-1.29) 0.78 (0.51-1.09)*** 1.07 (0.75-1.30) 0.63 (0.43-0.89)*** 
Ductus venosus pulsatility index for veins (MoM) 1.00 (0.90-1.09) 1.01 (0.91-1.15) 1.00 (0.88-1.10) 1.04 (0.94-1.17)** 
Uterine artery pulsatility index (MoM) 1.00 (0.81-1.22) 1.23 (0.97-1.52)*** 1.03 (0.83-1.34) 1.39 (1.14-1.61)*** 
 
MoM= multiple of the median; Post hoc Bonferroni correction for multiple comparisons; † = p< 0.01; * = p< 0.001 
 
 
Supplementary Table 3. Univariate and multivariate logistic regression analysis for the 
prediction of stillbirths due to impaired placentation by maternal factors and biomarkers at 11-
13 weeks’ gestation 
 
 
PAPP-A = pregnancy associated plasma protein-A; PlGF = placental growth factor; PI = 
pulsatility index; PIV = pulsatility index for veins; MoM= multiple of the median; OR = odds 
ratio; CI = confidence interval 
  
Variables 
Univariate analysis Multivariate analysis 
OR (95% CI) P value OR (95% CI) P value 
Maternal factor derived logit (a priori risk) 13.98 (8.55-22.88) <0.0001 8.77 (5.09-15.12) <0.0001 
Log10 PAPP-A MoM 0.19 (0.13-0.30) <0.0001   
Log10 PlGF MoM 0.008 (0.004-0.015) <0.0001 0.016 (0.008-0.030) <0.0001 
Log10 Ductus venosus PIV MoM 196.02 (36.86-1042.46) <0.0001 49.73 (7.86-314.52) <0.0001 
Log10 Uterine artery PI MoM 4.63e03 (1.02e03-20.91e03) <0.0001 713.01 (155.83-3262.38) <0.0001 
Figure 1. Box and whiskers plot of placental growth factor (PlGF) multiple of the median 
(MoM) in live births (a), unexplained stillbirths (b) and stillbirths due to impaired placentation 
(c). The bottom and top edges of each box represent the first and third quartiles, respectively; 
the band within the box represents the median value. 
   
Figure 2. Receiver–operating characteristics curves for prediction of stillbirth due to impaired 
placentation from maternal factors and maternal factors with biomarkers. 
 
